Company introduction

All categories



首页

/

Shanghai Staili Pharmaceutical Co., LTD

分类：Each subsidiary
Release time:2019-12-13 00:00:00
Visits:0

概要:

详情

　　Established in June 2012, Shanghai Stari Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of the listed company Zhejiang Stari Pharmaceutical Co., LTD. (Stock code: 603520), currently mainly engaged in the development and production of non-ionic contrast agent diagnostic drug preparations。The registered capital of the company is 100 million yuan, covers an area of 75 acres, has built 70,000 square meters of plants, the total asset scale of more than 500 million yuan。

　　The company currently has four production lines，They are large-capacity injection production line, small-capacity injection production line, cream (hormone) production line and gel production line，With Miconazole nitrate cream, Miconazole clobetasol cream, Lincomycin lidocaine gel, compound dexamethasone acetate cream four varieties of eight specifications of registration approval。

　　The company is the most critical link in the "strategic layout of the whole industrial chain of contrast media" of Stari Pharmaceutical。In 2020, the products declared by the company, such as iopasol injection, iohexyl injection and ioxaxol injection, were the first to pass the national new Class 4 registration (regarded as passing the "drug consistency evaluation") and obtained the registration approval of the State Drug Administration。In addition, the registration approval of two iodine contrast agent preparations of iodiformol injection and iodimepur injection is still pending approval by the State Drug Administration。Shanghai Stari Pharmaceutical Co., Ltd. has filled the gap in the pharmaceutical industry chain of Stari Pharmaceutical, and successfully completed the industrial transformation and upgrading from API to pharmaceutical expansion。